Dimension Therapeutics

Wall Street

Biotech

Bruised Ultragenyx attempts swoop for in-demand Dimension

Ultragenyx is putting up $138 million in cash to wrestle gene therapy biotech Dimension away from its first suitor.

Ben Adams Sep 18, 2017 10:00am

Nasdaq

Nightstar files for $86M IPO to fund gene therapy trials

Sep 1, 2017 8:02am

Ruhman joins NewcrestImage with more than 20 years of hospitality experience in senior management positions

Regenxbio to buy battered Dimension for gene therapies

Aug 25, 2017 9:04am